The study of ultrasound and iontophoresis on oxaprozin transdermal penetration using surface-enhanced Raman spectroscopy

  • Shupeng LiuEmail author
  • Xiang Bao
  • Songpo Zhang
  • Heng Zhang
  • Xiaofeng Lu
  • Taihao Li
  • Zhenyi Chen
  • Na ChenEmail author
Original Article


The potential for physicochemical driving forces facilitating topical transport of the lipid-soluble drug oxaprozin (OXA) was investigated using surface-enhanced Raman spectroscopy (SERS) in this study. Azone, iontophoresis (IP), and sonophoresis (SP) were combined and performed on mouse skin for the OXA transdermal penetration, and the synergistic effect was analyzed using Raman spectroscopy. The data of characteristic peak intensity were processed with overlapping peak resolving and standard normalization. The results showed that Azone promoted the transdermal penetration of OXA (5.9-fold greater than the OXA concentration of normal penetration); SP enhanced OXA transdermal penetration (5.5-fold); IP enhanced OXA transdermal penetration (4.2-fold); the combined application of Azone and SP (Azone+SP) and SP+IP can improve the enhancement coefficient of OXA transdermal penetration (8.4-fold and 6.1-fold, > 5.9, > 5.5, > 4.2), and their combined application has a synergistic effect; Azone+IP does not have a synergistic effect while the enhancement coefficient of Azone+IP (5.3-fold, < 5.9) and Azone+SP+IP (7.2-fold, < 8.4) was slightly reduced. As for the drug OXA, Azone+SP is an effective method of transdermal penetration.


Transdermal Sonophoresis Azone Iontophoresis Oxaprozin Raman spectrum 





surface-enhanced Raman spectroscopy






the combined application of Azone and SP


the combined application of Azone and IP


the combined application of SP and IP


the combined application of Azone and SP and IP


transdermal drug delivery system


stratum corneum






high-performance liquid chromatography


oleic acid


propylene glycol


sliver nitrate


analysis of variance

I1283 and I1660

the spectral peak integral intensities at 1283 cm−1 and 1660 cm−1

R1616/1283 and R1616/1660

The spectral peak intensity ratios of 1616 cm−1/1283 cm−1 and 1616 cm−1/1660 cm−1

R949/1283 and R949/1660

The spectral peak intensity ratios of 949 cm−1/1283 cm−1 and 949 cm−1/1660 cm−1



The authors wish to thank for the support of the Key Laboratory of Specialty Fiber Optics and Optical Access Networks (SKLSFO2017-02 and SKLSFO2018-05).

Funding information

This work was funded by Natural Science Foundation of China (NSFC) (61575120, 61475095).

Compliance with ethical standards

All institutional and national guidelines for the care and use of laboratory animals were followed. The experiments comply with the current laws of the country in which they were performed.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kalia YN, Naik A, Garrison J, Guy RH. Iontophoretic drug delivery. Adv Drug Deliv Rev. 2004;56(5):619–58.CrossRefGoogle Scholar
  2. 2.
    Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems: current and future prospects. Drug Delivery. 2006;13(3):175–87.CrossRefGoogle Scholar
  3. 3.
    Monti D, Giannelli R, Chetoni P, Burgalassi S. Comparison of the effect of ultrasound and of chemical enhancers on transdermal permeation of caffeine and morphine through hairless mouse skin in vitro. Int J Pharm. 2001;229(1–2):131–7.CrossRefGoogle Scholar
  4. 4.
    Hansen LS, Coggle JE, Wells J, Charles MW. The influence of the hair cycle on the thickness of mouse skin. Anat Rec. 1984;210(4):569–73.CrossRefGoogle Scholar
  5. 5.
    Shaji J, Varkey D. Recent advances in physical approaches for transdermal penetration enhancement. Curr Drug Ther. 2012;7(3):184–97.CrossRefGoogle Scholar
  6. 6.
    Walker RB, Smith EW. The role of percutaneous penetration enhancers. Adv Drug Deliv Rev. 1996;18(3):295–301.CrossRefGoogle Scholar
  7. 7.
    Hadgraft J, Peck J, Williams DG, Pugh WJ, Allan G. Mechanisms of action of skin penetration enhancers/retarders: Azone and analogues. Int J Pharm. 1996;141(1–2):17–25.CrossRefGoogle Scholar
  8. 8.
    Michniak BB, Player MR, Chapman JM Jr, Sowell JW Sr. Azone analogues as penetration enhancers: effect of different vehicles on hydrocortisone acetate skin permeation and retention. J Control Release. 1994;32(2):147–54.CrossRefGoogle Scholar
  9. 9.
    Singh P, Maibach HI. Iontophoresis: an alternative to the use of carriers in cutaneous drug delivery. Adv Drug Deliv Rev. 1996;18(3):379–94.CrossRefGoogle Scholar
  10. 10.
    Mitragotri S, Blankschtein D, Langer R. Transdermal drug delivery using low-frequency sonophoresis. Pharm Res. 1996;13(3):411–20.CrossRefGoogle Scholar
  11. 11.
    Hikima T, Ohsumi S, Shirouzu K, Tojo K. Mechanisms of synergistic skin penetration by sonophoresis and iontophoresis. Biol Pharm Bull. 2009;32(5):905–9.CrossRefGoogle Scholar
  12. 12.
    Beetge E, du Plessis J, Müller DG, Goosen C, van Rensburg FJ. The influence of the physicochemical characteristics and pharmacokinetic properties of selected NSAID’s on their transdermal absorption. Int J Pharm. 2000;193(2):261–4.CrossRefGoogle Scholar
  13. 13.
    Miller LG. Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug. Clin Pharm. 1992;11(7):591–603.Google Scholar
  14. 14.
    Ning W, Zhi-Yong L, Xiao-Li Z, et al. Quality assessment of Kumu injection, a traditional Chinese medicine preparation, using HPLC combined with chemometric methods and qualitative and quantitative analysis of multiple alkaloids by single marker. Molecules. 2018;23(4):856.CrossRefGoogle Scholar
  15. 15.
    Wegler C, Gaugaz FZ, Andersson TB, Wiśniewski JR, Busch D, Gröer C, et al. Variability in mass spectrometry-based quantification of clinically relevant drug transporters and drug metabolizing enzymes. Mol Pharm. 2017;14(9):3142–51.CrossRefGoogle Scholar
  16. 16.
    Xu Y, Du Y, Li Q, et al. Ultrasensitive detection of enrofloxacin in chicken muscles by surface-enhanced raman spectroscopy using amino-modified glycidyl methacrylate-ethylene dimethacrylate (GMA-EDMA) powdered porous material. Food Anal Methods. 2014;7(6):1219–28.CrossRefGoogle Scholar
  17. 17.
    Caspers PJ, Williams AC, Carter EA, Edwards HGM, Barry BW, Bruining HA, et al. Monitoring the penetration enhancer dimethyl sulfoxide in human SC in vivo by confocal Raman spectroscopy. Pharm Res. 2002;19(10):1577–80.CrossRefGoogle Scholar
  18. 18.
    Atef E, Altuwaijri N. Using raman spectroscopy in studying the effect of propylene glycol, oleic acid, and their combination on the rat skin. AAPS PharmSciTech. 2018;19(1):114–22.CrossRefGoogle Scholar
  19. 19.
    Lee PC, Meisel DJJ. Adsorption and surface-enhanced Raman of dyes on silver and god sols. J Phys Chem. 1982;86(17):3391–5.CrossRefGoogle Scholar
  20. 20.
    Zhang H, Chen Z, Li T, Chen N, Xu W, Liu S. Surface-enhanced Raman scattering spectra revealing the inter-cultivar differences for Chinese ornamental Flos Chrysanthemum: a new promising method for plant taxonomy. Plant Methods. 2017;13(1):92.CrossRefGoogle Scholar
  21. 21.
    Venter JP, Muller DG, Du Plessis J, et al. A comparative study of an in situ adapted diffusion cell and an in vitro Franz diffusion cell method for transdermal absorption of doxylamine. Eur J Pharm Sci. 2001;13(2):169–77.CrossRefGoogle Scholar
  22. 22.
    Sagdinc SG, Esme A. Theoretical and vibrational studies of 4, 5-diphenyl-2-2 oxazole propionic acid (oxaprozin). Spectrochim Acta A Mol Biomol Spectrosc. 2010;75(4):1370–6.CrossRefGoogle Scholar
  23. 23.
    Jursic BS. Hybrid and gradient-corrected density functional theory computations of the cubane infrared and Raman spectra. J Mol Struct THEOCHEM. 1997;394(1):15–8.CrossRefGoogle Scholar
  24. 24.
    Tfayli A, Piot O, Pitre F, Manfait M. Follow-up of drug permeation through excised human skin with confocal Raman microspectroscopy. Eur Biophys J. 2007;36(8):1049–58.CrossRefGoogle Scholar
  25. 25.
    Manabe E, Sugibayashi K, Morimoto Y. Analysis of skin penetration enhancing effect of drugs by ethanol-water mixed systems with hydrodynamic pore theory. Int J Pharm. 1996;129(1–2):211–21.CrossRefGoogle Scholar
  26. 26.
    Mennini N, Cirri M, Maestrelli F, Mura P. Comparison of liposomal and NLC (nanostructured lipid carrier) formulations for improving the transdermal delivery of oxaprozin: effect of cyclodextrin complexation. Int J Pharm. 2016;515(1–2):684–91.CrossRefGoogle Scholar
  27. 27.
    Kurihara-Bergstrom T, Knutson K, DeNoble LJ, Goates CY. Percutaneous absorption enhancement of an ionic molecule by ethanol–water systems in human skin. Pharm Res. 1990;7(7):762–6.CrossRefGoogle Scholar
  28. 28.
    Suhonen TM, Bouwstra JA, Urtti A. Chemical enhancement of percutaneous absorption in relation to stratum corneum structural alterations. J Control Release. 1999;59(2):149–61.CrossRefGoogle Scholar
  29. 29.
    Dujardin N, Staes E, Kalia Y, Clarys P, Guy R, Préat V. In vivo assessment of skin electroporation using square wave pulses. J Control Release. 2002;79(1–3):219–27.CrossRefGoogle Scholar
  30. 30.
    Mukaka MM. A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.Google Scholar

Copyright information

© Controlled Release Society 2019

Authors and Affiliations

  • Shupeng Liu
    • 1
    Email author
  • Xiang Bao
    • 1
  • Songpo Zhang
    • 1
  • Heng Zhang
    • 1
  • Xiaofeng Lu
    • 1
  • Taihao Li
    • 2
  • Zhenyi Chen
    • 1
  • Na Chen
    • 1
    Email author
  1. 1.Key Laboratory of Specialty Fiber Optics and Optical Access Networks, Joint International Research Laboratory of Specialty Fiber Optics and Advanced Communication, Shanghai Institute for Advanced Communication and Data Science, Institute of Biomedical Engineering, School of Communication and Information EngineeringShanghai UniversityShanghaiChina
  2. 2.College of Medical InstrumentsShanghai University of Medicine & Health SciencesShanghaiChina

Personalised recommendations